Today: 19 April 2026
DroneShield share price jumps as ASX:DRO rides defence bid into the close
2 March 2026
1 min read

DroneShield share price jumps as ASX:DRO rides defence bid into the close

Sydney, March 2, 2026, 18:24 AEDT — The market shut its doors for the day.

  • DroneShield rose 6.9%, closing at A$3.87.
  • Defence stocks caught buying interest as markets digested another jolt from the Middle East.
  • Coming up: Tuesday’s open, fresh action in oil, plus the latest on contract updates.

DroneShield Limited ended Monday’s session up 6.9% at A$3.87 in Sydney, with the stock outperforming most peers as traders bought into defence-focused names.

This shift stands out, highlighting just how quickly capital is shifting on headline moves. The wider ASX held its ground into the close, though the session’s gainers clustered in “hard” plays like energy, gold, and defence. Traders worked to price in a risk scenario where conflict might spread.

DroneShield’s surge came during a choppy stretch for risk assets. “It remains to be seen how long this conflict will continue,” Betashares chief economist David Bassanese said in comments to ABC News. AMP’s Shane Oliver, also a chief economist, cautioned that pricier oil could “act as a tax on households.” ABC News

DroneShield’s numbers have been making the case lately. The company, which specializes in counter-drone systems—tools to spot, follow, and jam unmanned aircraft used by military, police, and operators of essential infrastructure—sells into a space that’s drawing fresh attention.

DroneShield last week announced six separate deals totaling A$21.7 million. The contracts cover portable “dismounted” counter-drone systems, along with spares and software subscriptions. The company expects to deliver in the first quarter of 2026, with payments to follow in the second quarter.

Investors keep zeroing in on the timing of delivery and payment. Orders for defence tech have a way of coming in waves, and the money often lands only when the hardware does—not when the deal gets announced.

Of course, Monday’s pop could just as easily vanish. Should oil’s geopolitical premium unwind and risk appetites return, high-beta small caps are quick to surrender ground.

Traders are looking past the headlines to see if fresh orders materialize. The question now: can the company keep turning contract awards into actual shipments and cash in the coming quarter?

Traders are bracing for Tuesday, watching how crude and global futures respond after the weekend’s strikes—a situation that’s already rattled energy prices and dampened risk appetite.

Stock Market Today

  • 2 TSX Stocks Under $100 with Strong Upside Potential
    April 18, 2026, 9:56 PM EDT. CES Energy (TSX:CEU) and Bird Construction are two TSX-listed stocks priced below $100 that offer significant growth potential. CES Energy provides consumable chemical solutions to oil and gas producers, benefiting from rising service intensity and demand for advanced chemical treatments. Despite softer drilling activity, CES's revenue growth remains robust, supported by its asset-light model and strategic acquisitions. Macro trends like growing global energy demand and LNG infrastructure expansion further boost its outlook. Bird Construction, also trading under $100, stands out for its presence in the construction sector, which benefits from infrastructure spending and urban development. Both companies show disciplined capital allocation and resilient revenue drivers, making them attractive for investors seeking accessible entry points and potential capital appreciation on the TSX.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
Woolworths share price jumps nearly 2% as WOW ex-dividend date nears
Previous Story

Woolworths share price jumps nearly 2% as WOW ex-dividend date nears

Wesfarmers share price ends higher after ASX close as Bunnings-Uber Eats deal draws a complaint
Next Story

Wesfarmers share price ends higher after ASX close as Bunnings-Uber Eats deal draws a complaint

Go toTop